Theralase TechnologiesTLTFF +1.22%46 Days Payable is 1,202.68 as of Mar. 2026, which is 263% above its 10-year median of 331.27. GuruFocus rates TLTFF with a GF Score™ of 46/100 and a GF Value™ of $0.13 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 795 Medical Devices & Instruments companies, Theralase Technologies ranks better than 95.97% on this metric.
The historical rank and industry rank for Theralase Technologies's Days Payable or its related term are showing as below:
TLTFF'
s Days Payable Range Over the Past 10 Years
Min: 160.75 Med: 331.27 Max: 1218.93
Current: 1218.93
During the past 13 years, Theralase Technologies's highest Days Payable was 1218.93. The lowest was 160.75. And the median was 331.27.
TLTFF's Days Payable is ranked better than 95.97% of 795
companies
in the Medical Devices & Instruments industry
Industry Median: 67.87
vs TLTFF: 1218.93
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Theralase Technologies's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Theralase Technologies Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Theralase Technologies's Days Payable distribution charts can be found below:
* The bar in red indicates where Theralase Technologies's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Theralase Technologies's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Theralase Technologies (TLTFF) has a Days Payable of 1,202.68 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Theralase Technologies and its competitors. This is 263% above median its historical median of 331.27. Over the past decade, Theralase Technologies' Days Payable has ranged from 160.75 to 1,218.93. According to the industry distribution chart, Theralase Technologies ranks #32 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 4%.
Is Theralase Technologies' Days Payable too high?
Theralase Technologies' current Days Payable of 1,202.68 is 263% above median its 10-year median of 331.27. Over the past 10 years, this metric has ranged from a low of 160.75 to a high of 1,218.93. The Medical Devices & Instruments industry median Days Payable is 67.87. Theralase Technologies' value of 1,202.68 is 1672% above this industry median. Based on the distribution chart, Theralase Technologies ranks #32 out of 795 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Theralase Technologies has a GF Score™ of 46/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Theralase Technologies' Days Payable compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Theralase Technologies ranks #32 out of 795 companies for Days Payable. This places Theralase Technologies in the top 4% of its industry — outperforming the majority of peers. The industry median Days Payable is 67.87. Theralase Technologies' value of 1,202.68 is 1672% above this benchmark. Historically, Theralase Technologies' own Days Payable has ranged from 160.75 to 1,218.93 over the past decade. While the company's 10-year median is 331.27 vs. the industry median of 67.87, Theralase Technologies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 67.87, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Theralase Technologies's current Days Payable of 1,202.68 is 1672% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Theralase Technologies and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 67.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Theralase Technologies's current Days Payable is 1,202.68, which is 263% above median its own 10-year median of 331.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Theralase Technologies stock overvalued right now?
Based on GuruFocus' analysis, Theralase Technologies (TLTFF) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.13, compared to a current price of $0.17 — trading 28.1% above its estimated fair value. The current Days Payable is 1,202.68, which is 263% above median its 10-year median of 331.27 and 1672% above the Medical Devices & Instruments industry median of 67.87. Theralase Technologies' overall GF Score™ is 46/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Theralase Technologies (TLTFF), the current Days Payable is 1,202.68 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Theralase Technologies (TLTFF) Overvalued in 2026?
Based on GuruFocus' analysis, Theralase Technologies stock appears to be overvalued.
The current stock price of $0.17 is trading 28.1% above its estimated GF Value™ of $0.13.
GuruFocus considers Theralase Technologies to be Modestly Overvalued.
Key valuation signals for TLTFF:
Days Payable: 1,202.68 (263% above median its 10-year median of 331.27)
GF Value™: $0.13 vs. price of $0.17 (28.1% above fair value)
Industry Position: 1672% above the Medical Devices & Instruments median (#32 of 795)
No single metric tells the full story. See the TLTFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Theralase Technologies Inc brings CLT to patients and personalized ACT to patients based on individual tissue characteristics. It is two separate reportable operating divisions; the Drug Division and the Device Division. The Drug Division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs), and activates them with proprietary and patent-pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The Device Division designs develops, manufactures, and markets proprietary super-pulsed laser technology indicated and cleared by Health Canada and the Food and Drug Administration (FDA) for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions.
46GF Score
Get the complete analysis for TLTFF
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TLTFF has been successfully added to your 
